As global markets navigate a mixed start to the new year, with U.S. stocks closing out a strong 2024 despite some recent volatility, investors are keenly observing economic indicators like the Chicago PMI and GDP forecasts for signs of future trends. In this environment of fluctuating indices and economic uncertainty, identifying undervalued stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to optimize their portfolios.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Dime Community Bancshares (NasdaqGS:DCOM) |
US$30.89 |
US$61.61 |
49.9% |
|
Wasion Holdings (SEHK:3393) |
HK$7.05 |
HK$14.02 |
49.7% |
|
Tourmaline Oil (TSX:TOU) |
CA$66.79 |
CA$133.01 |
49.8% |
|
Camden National (NasdaqGS:CAC) |
US$42.08 |
US$83.90 |
49.8% |
|
S Foods (TSE:2292) |
¥2737.00 |
¥5472.35 |
50% |
|
Zhende Medical (SHSE:603301) |
CN¥21.00 |
CN¥41.99 |
50% |
|
Ally Financial (NYSE:ALLY) |
US$35.85 |
US$71.62 |
49.9% |
|
Shandong Weigao Orthopaedic Device (SHSE:688161) |
CN¥23.89 |
CN¥47.76 |
50% |
|
SkyCity Entertainment Group (NZSE:SKC) |
NZ$1.45 |
NZ$2.89 |
49.8% |
|
LG Energy Solution (KOSE:A373220) |
₩356000.00 |
₩709677.60 |
49.8% |
Here we highlight a subset of our preferred stocks from the screener.
Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across various international markets with a market cap of €1.44 billion.
Operations: The company’s revenue primarily comes from its oncology segment, which generated €154.75 million.
Estimated Discount To Fair Value: 48%
Pharma Mar is trading at €82.85, significantly below its estimated fair value of €159.19, suggesting it may be undervalued based on discounted cash flow analysis. Despite recent volatility and a slight decline in net income to €7.44 million for the first nine months of 2024, earnings are forecast to grow substantially at 56.2% annually over the next three years, outpacing the Spanish market’s growth rate. Revenue is also projected to increase by 25.4% per year, driven by positive clinical trial results for Zepzelca®.
Overview: Türk Telekomünikasyon Anonim Sirketi, along with its subsidiaries, offers integrated telecommunication services in Turkey and has a market cap of TRY159.53 billion.
